Search Result

Results for "

2C9

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Akt (2) Aldose Reductase (1) Antibiotic (3) Apoptosis (21) Atg8/LC3 (11) Autophagy (29) Bacterial (16) Bcl-2 Family (1) Calcium Channel (3) Cannabinoid Receptor (1) Cholinesterase (ChE) (1) COX (9) Cytochrome P450 (105) Dihydrofolate reductase (DHFR) (1) DNA/RNA Synthesis (1) Drug Derivative (1) Drug Metabolite (7) EGFR (1) Endogenous Metabolite (8) Endothelin Receptor (5) ERK (2) Fc Receptor (FcR) (1) Ferroptosis (1) FGFR (1) FLAP (1) Fluorescent Dye (1) Fungal (2) Glucocorticoid Receptor (2) Glycosidase (1) GPR119 (3) HBV (1) HCV Protease (2) HIV (2) Indoleamine 2,3-Dioxygenase (IDO) (2) Insecticide (2) Interleukin Related (11) Isotope-Labeled Compounds (16) JAK (1) Keap1-Nrf2 (1) Lactate Dehydrogenase (1) Liposome (2) Lysyl Oxidase (1) MAP3K (1) MEK (2) mGluR (1) Microtubule/Tubulin (1) Monocarboxylate Transporter (1) mTOR (2) Na+/K+ ATPase (11) NAMPT (1) Necroptosis (3) NF-κB (4) NO Synthase (4) NTPDase (6) OAT (1) Orexin Receptor (OX Receptor) (1) P2X Receptor (1) p38 MAPK (3) Parasite (7) PARP (1) PERK (1) PI3K (1) Potassium Channel (10) PPAR (10) Pregnane X Receptor (PXR) (2) Prostaglandin Receptor (1) Proton Pump (11) Pyruvate Kinase (1) RANKL/RANK (1) Reactive Oxygen Species (ROS) (2) Reference Standards (21) RET (1) Reverse Transcriptase (1) Ribosomal S6 Kinase (RSK) (2) ROCK (1) SARS-CoV (2) Serotonin Transporter (1) Small Interfering RNA (siRNA) (1) SOD (1) Sodium Channel (2) STAT (2) TGF-β Receptor (4) Thrombopoietin Receptor (7) TNF Receptor (11) UGT (2) URAT1 (3) Urease (1) Virus Protease (2) VKOR (1) Xanthine Oxidase (1)
By Research Areas:	Cancer (51) Cardiovascular Disease (34) Infection (31) Inflammation/Immunology (45) Metabolic Disease (33) Neurological Disease (24)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Cationic Lipids (1) Human Pre-designed siRNA Sets (1) siRNAs (1)

147

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N1201

Apigenin Maximum Cited Publications 45 Publications Verification 4',5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1	Autophagy Cytochrome P450 Endogenous Metabolite	Inflammation/Immunology Cancer
Apigenin (4',5,7-Trihydroxyflavone) is a competitive *CYP2C9* inhibitor with a K_i of 2 μM.

HY-17356

Fenofibrate 30+ Cited Publications	PPAR Cytochrome P450 Autophagy	Cardiovascular Disease Cancer
Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, *CYP2C9, CYP2C8, and CYP3A4*, respectively.

HY-15550

4'-Hydroxy diclofenac	Drug Metabolite	Neurological Disease Inflammation/Immunology
4'-Hydroxy diclofenac is an orally active metabolite of Diclofenac (HY-15036) by cytochrome P450 2C9 (CYP2C9). 4'-Hydroxy diclofenac has anti-inflammatory and analgesic properties .

HY-N0904

Ginsenoside C-K 5 Publications Verification Ginsenoside compound K; Ginsenoside K	COX NO Synthase Cytochrome P450	Inflammation/Immunology
Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects by reducing iNOS and COX-2. Ginsenoside C-K exhibits an inhibition against the activity of *CYP2C9* and CYP2A6 in human liver microsomes with IC₅₀s of 32.0±3.6 μM and 63.6±4.2 μM, respectively.

HY-B1218

Sulfaphenazole 10+ Cited Publications	Cytochrome P450 Antibiotic Bacterial Necroptosis Apoptosis	Infection Cardiovascular Disease
Sulfaphenazole is a selective inhibitor of human cytochrome P450 (CYP) 2C9 enzyme. Sulfaphenazole is a cytoprotective agent against light-induced death of photoreceptors. Sulfaphenazole inhibits light-induced necrosis and mitochondrial stress-initiated apoptosis. Sulfaphenazole is an off patent sulfonamide antibiotic and demonstrates bactericidal activity through enhanced M1 macrophage activity. Sulfaphenazole can significantly reduce infarct size and restore post-ischemic coronary flow following ischemia and reperfusion .

HY-B0258

Gemfibrozil 5+ Cited Publications CI-719	PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease Cancer
Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-11103

Sitaxsentan sodium 2 Publications Verification IPI 1040 sodium; TBC11251 sodium	Endothelin Receptor TGF-β Receptor	Cardiovascular Disease Metabolic Disease
Sitaxsentan sodium (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC₅₀ of 1.4 nM and a K_i of 0.43 nM. Sitaxsentan sodium exhibits an IC₅₀ for the ETB receptor of as high as 9800 nM. Sitaxsentan sodium is metabolized by *CYP2C9* and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan sodium can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension .

HY-15550S

4'-Hydroxy diclofenac-d4	Drug Metabolite	Neurological Disease Inflammation/Immunology
4'-Hydroxy diclofenac-d₄ is the deuterium labeled 4'-Hydroxy diclofenac. 4'-Hydroxy diclofenac is an orally active metabolite of Diclofenac (HY-15036) by cytochrome P450 2C9 (CYP2C9). 4'-Hydroxy diclofenac has anti-inflammatory and analgesic properties .

HY-N0893

Tetrahydrocurcumin 2 Publications Verification HZIV 81-2	Cytochrome P450 Autophagy Endogenous Metabolite	Inflammation/Immunology Cancer
Tetrahydrocurcumin is a Curcuminoid found in turmeric (Curcuma longa) that is produced by the reduction of Curcumin. Tetrahydrocurcumin inhibit *CYP2C9* and CYP3A4.

HY-100386

Ticlopidine 3 Publications Verification PCR 5332	NTPDase Cytochrome P450	Cardiovascular Disease
Ticlopidine (PCR 5332), an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC₅₀ of 81.7 μM. Ticlopidine blocks several NTPDase isoenzymes with IC₅₀s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively. Ticlopidine is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine inhibits CYP2C9 and CYP3A4 with IC₅₀s of 26.0 and 32.3 μM, respectively.

HY-13463

Avatrombopag 5 Publications Verification AKR-501; E5501; YM477	Thrombopoietin Receptor	Inflammation/Immunology Cancer
Avatrombopag (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC₅₀=3.3 nM). Avatrombopag mimics the biological activities of TPO. Avatrombopag increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

HY-B0153A

Ticlopidine hydrochloride 3 Publications Verification	NTPDase Cytochrome P450	Cardiovascular Disease Neurological Disease Cancer
Ticlopidine (PCR 5332) hydrochloride, an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC₅₀ of 81.7 μM. Ticlopidine hydrochloride blocks several NTPDase isoenzymes with IC₅₀s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively. Ticlopidine hydrochloride is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine hydrochloride inhibits CYP2C9 and CYP3A4 with IC₅₀s of 26.0 and 32.3 μM, respectively .

HY-N0911

Rehmannioside A 1 Publications Verification	NF-κB Apoptosis p38 MAPK Ferroptosis Cytochrome P450 Reactive Oxygen Species (ROS) SOD Lactate Dehydrogenase PERK MEK Bcl-2 Family NO Synthase COX PARP	Neurological Disease Inflammation/Immunology
Rehmannioside A is a compound that can be isolated from Rehmanniae radix. Rehmannioside A is an inhibitor of CYP3A4, *2C9* and 2D6, with IC₅₀ values of 10.08, 12.62 and 16.43 μM, respectively. Rehmannioside A has anti-inflammatory, antioxidant, anti-apoptosis, anti-ferroptosis, cognitive improvement and neuroprotective activities. Rehmannioside A can be used for the research of nervous system and inflammation-related diseases .

HY-N0920

Dihydrokavain 7,8-Dihydrokawain; 7,8-Dihydrokavain; Marindinin	COX Cytochrome P450	Neurological Disease Inflammation/Immunology
Dihydrokavain (7,8-Dihydrokawain) is a natural kavalactone compound. Dihydrokavain inhibits COX-1, COX-2, *CYP2C9* (IC₅₀ = 130.95 μM), CYP2C19 (IC₅₀ = 10.05 μM) and CYP3A4 (IC₅₀ = 78.59 μM). Dihydrokavain reduces TNFα secretion. Dihydrokavain shows analgesic and anxiolytic effects .

HY-N0688

Linderane	Cytochrome P450	Inflammation/Immunology
Linderane, isolated from the root of Lindera aggregata, is an irreversible inhibitor cytochrome P450 2C9 (CYP2C9). Linderane has the potential to relieve pain and cramp .

HY-13463A

Avatrombopag maleate 5 Publications Verification AKR-501 maleate; E5501 maleate; YM477 maleate	Thrombopoietin Receptor Cytochrome P450 ERK STAT	Inflammation/Immunology Cancer
Avatrombopag (AKR-501) maleate is an orally active, non-peptide thrombopoietin receptor (TPO receptor) agonist (EC₅₀: 3.3 nM). Avatrombopag maleate mimics the biological activity of TPO. Avatrombopag maleate increases platelet production by activating intracellular signaling systems and promotes the production of platelets and megakaryocytes from hematopoietic precursor cells. Avatrombopag maleate is a substrate for cytochrome P450 (CYP) 2C9 and CYP3A .

HY-117026

LKY-047 1 Publications Verification	Cytochrome P450	Metabolic Disease Inflammation/Immunology
LKY-047, a Decursin derivative, is a potent and selective reversible competitive cytochrome P45022J2 (CYP2J2) inhibitor with an IC₅₀ of 1.7 μM. LKY-047 is inactive against other human P450s, such as CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A .

HY-15565

APD668 2 Publications Verification	GPR119 Cytochrome P450 Potassium Channel	Metabolic Disease
APD668 is a potent, selective and orally active agonist of G-protein coupled receptor GPR119, with EC₅₀s of 2.7 nM and 33 nM for hGPR119 and rGPR119, respectively. APD668 shows no significant inhibition of any of the five major CYP isoforms with the exception of *CYP2C9* (K_i=0.1 μM). APD668 can be used for the research of steatohepatitis and diabetes .

HY-100641

4-Hydroxytolbutamide Hydroxytolbutamide	Potassium Channel Autophagy	Metabolic Disease Cancer
4-Hydroxytolbutamide (Hydroxytolbutamide) is a metabolite of Tolbutamide. 4-Hydroxytolbutamide is metabolized by CYP2C8 and CYP2C9. Tolbutamide is a first generation potassium channel blocker and a sulfonylurea oral antidiabetic .

HY-15566

APD597 1 Publications Verification JNJ-38431055	GPR119	Metabolic Disease
APD597 (JNJ-38431055) is an orally active agonist of GPR119. APD597 exhibits reduced *CYP2C9* inhibition with an IC₅₀ of 5.8 μM. APD597 can be studied in research for type 2 diabetes .

HY-N6023

Thermopsoside	Cytochrome P450 Pregnane X Receptor (PXR)	Others
Thermopsoside is a CYP450 isoenzyme inhibitor and PXR activator. Thermopsoside inhibits CYP3A4, CYP2C19, CYP2D6 and CYP2C9 with IC₅₀ values of 6.0 μM, 9.5 μM, 12.0 μM and 32.0 μM, respectively .

HY-148822

Nampt activator-2	NAMPT	Neurological Disease
Nampt activator-2 (compound 34) is a potent NAMPT activator, with EC₅₀ of 0.023 μM. Nampt activator-2 shows moderate activity against CYP2C9 (0.060 μM), 2D6 (0.41 μM) and 2C19 (0.59 μM) .

HY-W013268

(S)-(+)-N-3-Benzylnirvanol (+)-N-3-Benzylnirvanol	Cytochrome P450	Metabolic Disease
(S)-(+)-N-3-Benzylnirvanol ((+)-N-3-Benzylnirvanol) is a selective and competitive cytochrome P450 (CYP) isoform CYP2C19 inhibitor with a K_i of 250 nM. (S)-(+)-N-3-Benzylnirvanol has low activity against CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2D6, CYP2E1, and CYP3A4 .

HY-116862

Dibenzylfluorescein DBF	Cytochrome P450 Fluorescent Dye	Others
Dibenzylfluorescein (DBF) is a fluorogenic probe (Fluoresecent dye) that acts as a substrate for specific cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2C8, CYP2C9, CYP2C19, and aromatase (CYP19). Dibenzylfluorescein is typically used near its K_m value of 0.87-1.9 μM (Ex=485 nm，Em=535 nm). Dibenzylfluorescein is used to detect changes in CYP catalytic activity caused by drugs or disease .

HY-17356S

Fenofibrate-d6	Isotope-Labeled Compounds PPAR Cytochrome P450 Autophagy	Cardiovascular Disease Cancer
Fenofibrate-d₆ is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-170538

SNT-5382	Lysyl Oxidase Cytochrome P450	Cardiovascular Disease Metabolic Disease
SNT-5382 is a lysyl oxidase family (LOX) inhibitor and anti-fibrotic agent. SNT-5382 binds to the LTQ cofactor of LOXL2 and inhibits the enzymatic activities of LOXL3, LOXL4, LOXL1, *CYP2C9, and CYP2C19*. SNT-5382 reduces cardiac and liver fibrosis as well as collagen crosslinks, and improves cardiac function. SNT-5382 can be used for the research of heart failure, myocardial infarction, and nonalcoholic steatohepatitis-related liver fibrosis .

HY-N1201R

Apigenin (Standard) Maximum Cited Publications 45 Publications Verification 4',5,7-Trihydroxyflavone(Standard); Apigenol(Standard); C.I. Natural Yellow 1 (Standard)	Reference Standards Autophagy Cytochrome P450 Endogenous Metabolite	Inflammation/Immunology Cancer
Apigenin (Standard) is the analytical standard of Apigenin. This product is intended for research and analytical applications. Apigenin (4',5,7-Trihydroxyflavone) is a competitive *CYP2C9* inhibitor with a K_i of 2 μM.

HY-100641S

4-Hydroxytolbutamide-d9 Hydroxytolbutamide-d₉	Potassium Channel Autophagy	Metabolic Disease Cancer
4-Hydroxytolbutamide-d₉ is the deuterium labeled 4-Hydroxytolbutamide. 4-Hydroxytolbutamide (Hydroxytolbutamide) is a metabolite of Tolbutamide. 4-Hydroxytolbutamide is metabolized by CYP2C8 and CYP2C9. Tolbutamide is a first generation potassium channel blocker and a sulfonylurea oral antidiabetic .

HY-128859

EMT inhibitor-2	Cytochrome P450	Metabolic Disease
EMT inhibitor-2 (Compound 1) inhibits epithelial-mesenchymal transition (EMT) induced by substances such as IL-1β and TGF-β released from the immunocytes. EMT inhibitor-2 inhibits CYP3A4 testosteron and CYP2C9 with IC₅₀s of 49.72 and 5.54 μM, respectively .

HY-114759

MS-PPOH 1 Publications Verification	Cytochrome P450	Neurological Disease Metabolic Disease Cancer
MS-PPOH is a potent and selective cytochrome P450 (CYP) epoxygenase inhibitor . MS-PPOH inhibits CYP2C8 and *CYP2C9* with IC₅₀s of 15 and 11 μM, respectively . MS-PPOH is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-17356R

Fenofibrate (Standard) 30+ Cited Publications	Reference Standards PPAR Cytochrome P450 Autophagy	Cardiovascular Disease Cancer
Fenofibrate (Standard) is the analytical standard of Fenofibrate. This product is intended for research and analytical applications. Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, *CYP2C9, CYP2C8, and CYP3A4*, respectively.

HY-15550R

4'-Hydroxy diclofenac (Standard)	Reference Standards Drug Metabolite	Neurological Disease Inflammation/Immunology
4'-Hydroxy diclofenac (Standard) is the analytical standard of 4'-Hydroxy diclofenac. This product is intended for research and analytical applications. 4'-Hydroxy diclofenac is an orally active metabolite of Diclofenac (HY-15036) by cytochrome P450 2C9 (CYP2C9). 4'-Hydroxy diclofenac has anti-inflammatory and analgesic properties .

HY-U00048

Bucolome Paramidin; Paramidine	Cytochrome P450	Inflammation/Immunology
Bucolome is a *CYP2C9* inhibitor, used as an uricosuric agent or anti-inflammatory agent.

HY-N1201S

Apigenin-d5	Isotope-Labeled Compounds Endogenous Metabolite Autophagy Cytochrome P450	Inflammation/Immunology
Apigenin-d5 is a deuterated labeled Apigenin . Apigenin (4',5,7-Trihydroxyflavone) is a competitive *CYP2C9* inhibitor with a K_i of 2 μM.

HY-N0893R

Tetrahydrocurcumin (Standard) HZIV 81-2 (Standard)	Reference Standards Cytochrome P450 Autophagy Endogenous Metabolite	Inflammation/Immunology Cancer
Tetrahydrocurcumin (Standard) is the analytical standard of Tetrahydrocurcumin. This product is intended for research and analytical applications. Tetrahydrocurcumin is a Curcuminoid found in turmeric (Curcuma longa) that is produced by the reduction of Curcumin. Tetrahydrocurcumin inhibit CYP2C9 and CYP3A4.

HY-13463B

Avatrombopag hydrochloride 5 Publications Verification AKR-501 hydrochloride; E5501 hydrochloride; YM477 hydrochloride	Thrombopoietin Receptor	Cardiovascular Disease Cancer
Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC₅₀=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

HY-B0258S

Gemfibrozil-d6 CI-719-d₆	PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease
Gemfibrozil-d₆ is the deuterium labeled Gemfibrozil. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-B0258R

Gemfibrozil (Standard) 5+ Cited Publications CI-719 (Standard)	Reference Standards PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease Cancer
Gemfibrozil (Standard) is the analytical standard of Gemfibrozil. This product is intended for research and analytical applications. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-114415

AWZ1066S	Parasite	Infection
AWZ1066S is a highly potent, specific and orally active anti-Wolbachia agent with EC₅₀ value of 121 nM. AWZ1066S also is a weak CYP2C9 inhibitor and a weak CYP3A4 inducer with IC₅₀ values of 9.7 μM and 37 uM, respectively. AWZ1066S can be used for the research of tropical diseases such as Onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis) .

HY-W130610R

Stearamide (Standard)	Liposome Reference Standards Akt mTOR	Others
Ginsenoside C-K (Standard) is the analytical standard of Ginsenoside C-K. This product is intended for research and analytical applications. Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects by reducing iNOS and COX-2. Ginsenoside C-K exhibits an inhibition against the activity of CYP2C9 and CYP2A6 in human liver microsomes with IC50s of 32.0±3.6 μM and 63.6±4.2 μM, respectively.

HY-76520

Sitaxsentan IPI 1040; TBC-11251	Endothelin Receptor TGF-β Receptor	Cardiovascular Disease Metabolic Disease
Sitaxsentan (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC₅₀ of 1.4 nM and a K_i of 0.43 nM. Sitaxsentan exhibits an IC₅₀ for the ETB receptor of as high as 9800 nM. Sitaxsentan is metabolized by *CYP2C9* and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension .

HY-105408A

Fandosentan potassium	Endothelin Receptor Cytochrome P450	Cardiovascular Disease
Fandosentan potassium is a potent endothelin A receptor (ET_AR) antagonist. Fandosentan potassium inhibits *CYP2C9* and CYP3A4 activities with IC₅₀ values of 39.6 and 21.6 μM, respectively. Fandosentan potassium reverses the hypoxic pulmonary vasoconstriction in the perinatal lamb. Fandosentan potassium can be used for pulmonary hypertension research ^[1][2].

HY-167872

Bifeprofen	Cytochrome P450	Others
Bifeprofen, a cytochrome P450 2C9 (CYP2C9) inhibitor, exhibits dose-dependent inhibition (75 μM, 50%) .

HY-131495

(S)-6-O-Desmethylnaproxen (S)-6-Desmethyl Naproxen	COX	Inflammation/Immunology
(S)-6-O-Desmethylnaproxen ((S)-6-Desmethyl Naproxen) is a metabolite of the non-steroidal anti-inflammatory drug (NSAID) and COX inhibitor (+)-naproxen ((S)-naproxen). (S)-6-O-Desmethylnaproxen is formed from (S)-naproxen by the cytochrome P450 (CYP) isoforms CYP1A2 and CYP2C9.

HY-13463BS

Avatrombopag-d8 hydrochloride AKR-501-d8 hydrochloride; E5501-d8 hydrochloride; YM477-d8 hydrochloride	Isotope-Labeled Compounds Thrombopoietin Receptor	Cardiovascular Disease
Avatrombopag-d₈ (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC₅₀=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

HY-N0904R

Ginsenoside C-K (Standard) Ginsenoside compound K(Standard); Ginsenoside K (Standard)	Reference Standards COX NO Synthase Cytochrome P450	Inflammation/Immunology
Ginsenoside C-K (Standard) is the analytical standard of Ginsenoside C-K. This product is intended for research and analytical applications. Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects by reducing iNOS and COX-2. Ginsenoside C-K exhibits an inhibition against the activity of CYP2C9 and CYP2A6 in human liver microsomes with IC50s of 32.0±3.6 μM and 63.6±4.2 μM, respectively.

HY-13463R

Avatrombopag (Standard) AKR-501 (Standard); E5501 (Standard); YM477 (Standard)	Reference Standards Thrombopoietin Receptor	Inflammation/Immunology Cancer
Avatrombopag (Standard) is the analytical standard of Avatrombopag. This product is intended for research and analytical applications. Avatrombopag (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC₅₀=3.3 nM). Avatrombopag mimics the biological activities of TPO. Avatrombopag increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

HY-117160

4-trans-Hydroxy-glibenclamide 4-trans-hydroxycyclohexyl Glyburide; 4-trans-hydroxy Glibenclamide	Potassium Channel	Neurological Disease
rac-trans-4-hydroxy Glyburide is an active metabolite of the SUR1/Kir6.2 sulfonylurea inhibitor glyburide (HY-15206). It is formed from glyburide by the cytochrome P450 (CYP) isoforms CYP2C8 and CYP2C9. rac-trans-4-hydroxy Glyburide inhibits glyburide binding to rat brain synaptosomes at the high and low affinity sites of SUR1/Kir6.2 with IC₅₀ values of 0.95 and 100 nM, respectively.

HY-B1218R

Sulfaphenazole (Standard)	Reference Standards Cytochrome P450 Antibiotic Bacterial Necroptosis Apoptosis	Infection Cardiovascular Disease
Sulfaphenazole (Standard) is the analytical standard of Sulfaphenazole. This product is intended for research and analytical applications. Sulfaphenazole is a selective inhibitor of human cytochrome P450 (CYP) 2C9 enzyme. Sulfaphenazole is a cytoprotective agent against light-induced death of photoreceptors. Sulfaphenazole inhibits light-induced necrosis and mitochondrial stress-initiated apoptosis. Sulfaphenazole is an off patent sulfonamide antibiotic and demonstrates bactericidal activity through enhanced M1 macrophage activity. Sulfaphenazole can significantly reduce infarct size and restore post-ischemic coronary flow following ischemia and reperfusion .

HY-151251

CYP2C9/CYP2C19-IN-1	Cytochrome P450 Virus Protease	Infection
CYP2C9/CYP2C19-IN-1 (compound 22d) is a potent *CYP2C9/CYP2C19* inhibitor, possessing no hepatotoxicity and ames toxicity. CYP2C9/CYP2C19-IN-1 can be used in study of anti-ZIKV .

Cat. No.	Product Name	Type

HY-116862

Dibenzylfluorescein

DBF

Fluorescent Dyes

Dibenzylfluorescein (DBF) is a fluorogenic probe (Fluoresecent dye) that acts as a substrate for specific cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2C8, CYP2C9, CYP2C19, and aromatase (CYP19). Dibenzylfluorescein is typically used near its K_m value of 0.87-1.9 μM (Ex=485 nm，Em=535 nm). Dibenzylfluorescein is used to detect changes in CYP catalytic activity caused by drugs or disease .

HY-17356G

Fenofibrate

Fluorescent Dyes

Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

Cat. No.	Product Name	Type

HY-153371

50-C2-C9-4tail	Biochemical Assay Reagents
50-C2-C9-4tail has been used in the generation of lipid nanoparticles (LNPs) for the delivery of siRNA and mRNA in vitro and in vivo.

HY-17356G

Fenofibrate

Biochemical Assay Reagents

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1201

Apigenin Maximum Cited Publications 45 Publications Verification 4',5,7-Trihydroxyflavone; Apigenol; C.I. Natural Yellow 1	Structural Classification Classification of Application Fields Flavones Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Sunscreen Phenols Polyphenols Cosmetic Research Umbelliferae Baccharis sarothroides A.Gray Disease Research Fields Source Classification Cancer	Autophagy Cytochrome P450 Endogenous Metabolite
Apigenin (4',5,7-Trihydroxyflavone) is a competitive *CYP2C9* inhibitor with a K_i of 2 μM.

HY-N6972

Cepharanthine 10+ Cited Publications	Infection Alkaloids Stephania cepharantha Hayata Classification of Application Fields Plants Isoquinoline Alkaloids Menispermaceae Inflammation/Immunology Disease Research Fields Stephania japonica (Thunb.) Miers	Autophagy SARS-CoV Cytochrome P450 Apoptosis Parasite
Cepharanthine is a natural product that can be isolated from the plant Stephania cephalantha Hayata. Cepharanthine has anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) activities. Cepharanthine has good effective in suppressing viral proliferation (half maximal (50%) inhibitory concentration (IC₅₀) and 90% inhibitory concentration (IC₉₀) values of 1.90 and 4.46 μM . Cepharanthine can also effectively reverses P-gp-mediated multidrug resistance in K562 cells and increase enhances the sensitivity of anticancer agents in xenograft mice model . Cepharanthine shows inhibitory effects of human liver cytochrome P450 enzymes CYP3A4, CYP2E1 and CYP2C9. Cepharanthine has antitumor, anti-inflammatory and antinociceptive effects .

HY-N0904

Ginsenoside C-K 5 Publications Verification Ginsenoside compound K; Ginsenoside K	Panax ginseng C. A. Meyer Triterpenes Classification of Application Fields Terpenoids Plants Inflammation/Immunology Disease Research Fields Araliaceae Source Classification	COX NO Synthase Cytochrome P450
Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects by reducing iNOS and COX-2. Ginsenoside C-K exhibits an inhibition against the activity of *CYP2C9* and CYP2A6 in human liver microsomes with IC₅₀s of 32.0±3.6 μM and 63.6±4.2 μM, respectively.

HY-N0043

Ginsenoside Rd 1 Publications Verification Gypenoside VIII	Panax ginseng C. A. Meyer Cardiovascular Disease Triterpenes Classification of Application Fields Terpenoids Plants Endogenous metabolite Disease Research Fields Araliaceae Source Classification Cancer	NF-κB COX Calcium Channel Cytochrome P450 Endogenous Metabolite
Ginsenoside Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC₅₀ of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of COX-2 and iNOS mRNA. Ginsenoside Rd also inhibits Ca ²⁺ influx. Ginsenoside Rd inhibits CYP2D6, CYP1A2, CYP3A4, and *CYP2C9, with IC₅₀*s of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM, and 85.1±9.1 μM, respectively.

HY-N0893

Tetrahydrocurcumin 2 Publications Verification HZIV 81-2	Classification of Application Fields Anti-aging Plants Endogenous metabolite Microorganisms Phenols Polyphenols Curcuma longa Inflammation/Immunology Disease Research Fields Source Classification Zingiberaceae Cancer	Cytochrome P450 Autophagy Endogenous Metabolite
Tetrahydrocurcumin is a Curcuminoid found in turmeric (Curcuma longa) that is produced by the reduction of Curcumin. Tetrahydrocurcumin inhibit *CYP2C9* and CYP3A4.

HY-N0911

Rehmannioside A 1 Publications Verification	Structural Classification Iridoids Classification of Application Fields Terpenoids Other Diseases Scrophulariaceae Plants Rehmannia glutinosa (Gaert.) Libosch. ex Fisch. et Mey Disease Research Fields Source Classification	NF-κB Apoptosis p38 MAPK Ferroptosis Cytochrome P450 Reactive Oxygen Species (ROS) SOD Lactate Dehydrogenase PERK MEK Bcl-2 Family NO Synthase COX PARP
Rehmannioside A is a compound that can be isolated from Rehmanniae radix. Rehmannioside A is an inhibitor of CYP3A4, *2C9* and 2D6, with IC₅₀ values of 10.08, 12.62 and 16.43 μM, respectively. Rehmannioside A has anti-inflammatory, antioxidant, anti-apoptosis, anti-ferroptosis, cognitive improvement and neuroprotective activities. Rehmannioside A can be used for the research of nervous system and inflammation-related diseases .

HY-N0920

Dihydrokavain 7,8-Dihydrokawain; 7,8-Dihydrokavain; Marindinin	Structural Classification Natural Products other families Plants Source Classification	COX Cytochrome P450
Dihydrokavain (7,8-Dihydrokawain) is a natural kavalactone compound. Dihydrokavain inhibits COX-1, COX-2, *CYP2C9* (IC₅₀ = 130.95 μM), CYP2C19 (IC₅₀ = 10.05 μM) and CYP3A4 (IC₅₀ = 78.59 μM). Dihydrokavain reduces TNFα secretion. Dihydrokavain shows analgesic and anxiolytic effects .

HY-N0762

Isobavachin 5 Publications Verification	Structural Classification Flavonoids Neurological Disease Classification of Application Fields Leguminosae Flavonones Phenols Polyphenols Psoralea corylifolia L. Plants Disease Research Fields Source Classification	Cytochrome P450 UGT p38 MAPK NF-κB NO Synthase COX Fc Receptor (FcR) RANKL/RANK Keap1-Nrf2 Reactive Oxygen Species (ROS) Apoptosis Autophagy
Isobavachin is an orally active, blood-brain barrier-penetrating prenylated flavonoid present in Psoralea corylifolia. Isobavachin inhibits human CYP2B6, *CYP2C9, CYP2C19, UGT1A1, UGT1A9, and UGT2B7. Isobavachin suppresses MAPK* activation, NF-κB nuclear translocation, overexpression of iNOS/COX-2, FcεRI-mediated signaling pathways, and RANKL-induced osteoclastogenesis. Isobavachin induces autophagy, cytotoxicity, neuronal differentiation, and NRF2 activation; it alleviates oxidative damage, inflammatory responses, apoptosis, iron accumulation, mitochondrial biogenesis, and mast cell degranulation. Isobavachin is applicable to research related to liver injury, inflammatory diseases, osteoporosis, liver cancer, prostate cancer, glioma, periodontitis-induced bone loss, and Alzheimer's disease .

HY-N0688

Linderane	Classification of Application Fields Terpenoids Sesquiterpenes Plants Lauraceae Lindera aggregata (Sims) Kosterm. Inflammation/Immunology Disease Research Fields Source Classification	Cytochrome P450
Linderane, isolated from the root of Lindera aggregata, is an irreversible inhibitor cytochrome P450 2C9 (CYP2C9). Linderane has the potential to relieve pain and cramp .

HY-N5132

(-)-Fenchone	Structural Classification Other Monoterpenes Classification of Application Fields Terpenoids Other Diseases Umbelliferae Plants Vernonia Schreb. Disease Research Fields Source Classification	Cytochrome P450
(-)-Fenchone is a bicyclic monoterpene and serves as a substrate for human liver microsomal cytochrome P450 enzymes CYP2A6 and CYP2B6. (-)-Fenchone is not metabolized by human CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 enzymes. (-)-Fenchone undergoes hydroxylation to produce 6-exo-hydroxyfenchone, 6-endo-hydroxyfenchone, and 10-hydroxyfenchone. During the metabolism of (-)-Fenchone, CYP2A6 may play a more important role than CYP2B6 .

HY-N6023

Thermopsoside	Structural Classification Flavonoids Classification of Application Fields Flavones Astragalus microcephalus Willd. Other Diseases Phenols Polyphenols Plants Compositae Disease Research Fields Source Classification	Cytochrome P450 Pregnane X Receptor (PXR)
Thermopsoside is a CYP450 isoenzyme inhibitor and PXR activator. Thermopsoside inhibits CYP3A4, CYP2C19, CYP2D6 and CYP2C9 with IC₅₀ values of 6.0 μM, 9.5 μM, 12.0 μM and 32.0 μM, respectively .

HY-N1050

Zederone	Terpenoids Sesquiterpenes Plants Curcuma elata Roxb. Source Classification Zingiberaceae	mTOR Ribosomal S6 Kinase (RSK) Bacterial
Zederone is a sesquiterpene. Zederone inhibits ovarian cancer cell proliferation through mTOR/p70s6K signalling pathway. Zederone inhibits CYP activities with IC₅₀s of 2.9 μM (CYP2B6), 9.2 μM (CYP2C9), 11,2 μM (CYP2C19) and >30 μM (CYP1A2 and CYP2D6). Zederone is hepatotoxic with LD₅₀ value at 24 hours in mice of approximately 223 mg/kg and cytotoxic against the KG1a cell line. Zederone shows antibacterial activity against a number of multi-drug resistant and Methicillin (HY-121544)-resistant Staphylococcus aureus strain. Zederone shows cognition improving capacity and assists in the modulation of gut bacterial dysbiosis .

HY-N1201R

Apigenin (Standard) Maximum Cited Publications 45 Publications Verification 4',5,7-Trihydroxyflavone(Standard); Apigenol(Standard); C.I. Natural Yellow 1 (Standard)	Classification of Application Fields Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Sunscreen Phenols Cosmetic Research Umbelliferae Baccharis sarothroides A.Gray Disease Research Fields Source Classification Cancer	Reference Standards Autophagy Cytochrome P450 Endogenous Metabolite
Apigenin (Standard) is the analytical standard of Apigenin. This product is intended for research and analytical applications. Apigenin (4',5,7-Trihydroxyflavone) is a competitive *CYP2C9* inhibitor with a K_i of 2 μM.

HY-N0893R

Tetrahydrocurcumin (Standard) HZIV 81-2 (Standard)	Structural Classification Microorganisms Phenols Polyphenols Plants Curcuma longa Endogenous metabolite Source Classification Zingiberaceae	Reference Standards Cytochrome P450 Autophagy Endogenous Metabolite
Tetrahydrocurcumin (Standard) is the analytical standard of Tetrahydrocurcumin. This product is intended for research and analytical applications. Tetrahydrocurcumin is a Curcuminoid found in turmeric (Curcuma longa) that is produced by the reduction of Curcumin. Tetrahydrocurcumin inhibit CYP2C9 and CYP3A4.

HY-W130610R

Stearamide (Standard)	Structural Classification Natural Products Microorganisms Source Classification	Liposome Reference Standards Akt mTOR
Ginsenoside C-K (Standard) is the analytical standard of Ginsenoside C-K. This product is intended for research and analytical applications. Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects by reducing iNOS and COX-2. Ginsenoside C-K exhibits an inhibition against the activity of CYP2C9 and CYP2A6 in human liver microsomes with IC50s of 32.0±3.6 μM and 63.6±4.2 μM, respectively.

HY-N8382

Chalepensin	Structural Classification Natural Products Haloxylon ammodendron (C. A. Mey.) Bunge Amaranthaceae Plants Source Classification	Cytochrome P450 Parasite Insecticide
Chalepensin is a nematicide and CYP inhibitor. Chalepensin inhibits CYP2A6, CYP1A1, CYP1A2, CYP2A13, *CYP2C9, CYP2D6, CYP2E1, and CYP3A4* to varying degrees, with IC₅₀ values of 82.3 μM, 2.86 μM, 3.01 μM, 0.21 μM, 6.58 μM, 1.67 μM, 61.1 μM, and 61.7 μM, respectively. Chalepensin potently and selectively kills third-stage infective larvae of Strongyloides venezuelensis .

HY-N0904R

Ginsenoside C-K (Standard) Ginsenoside compound K(Standard); Ginsenoside K (Standard)	Panax ginseng C. A. Meyer Triterpenes Structural Classification Classification of Application Fields Terpenoids Plants Inflammation/Immunology Disease Research Fields Araliaceae Source Classification	Reference Standards COX NO Synthase Cytochrome P450
Ginsenoside C-K (Standard) is the analytical standard of Ginsenoside C-K. This product is intended for research and analytical applications. Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects by reducing iNOS and COX-2. Ginsenoside C-K exhibits an inhibition against the activity of CYP2C9 and CYP2A6 in human liver microsomes with IC50s of 32.0±3.6 μM and 63.6±4.2 μM, respectively.

HY-N0688R

Linderane (Standard)	Terpenoids Sesquiterpenes Plants Lauraceae Lindera aggregata (Sims) Kosterm. Source Classification	Reference Standards Cytochrome P450
Linderane (Standard) is the analytical standard of Linderane. This product is intended for research and analytical applications. Linderane, isolated from the root of Lindera aggregata, is an irreversible inhibitor cytochrome P450 2C9 (CYP2C9). Linderane has the potential to relieve pain and cramp .

HY-N6972R

Cepharanthine (Standard)	Structural Classification Alkaloids Stephania cepharantha Hayata Plants Isoquinoline Alkaloids Menispermaceae Stephania japonica (Thunb.) Miers	Autophagy Reference Standards SARS-CoV Cytochrome P450 Apoptosis Parasite
Cepharanthine (Standard) is the analytical standard of Cepharanthine. This product is intended for research and analytical applications. Cepharanthine is a natural product that can be isolated from the plant Stephania?cephalantha?Hayata. Cepharanthine has anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) activities. Cepharanthine has good effective in suppressing viral proliferation (half maximal (50%) inhibitory concentration (IC₅₀) and 90% inhibitory concentration (IC90) values of 1.90 and 4.46?μM . Cepharanthine can also effectively reverses P-gp-mediated multidrug resistance in K562 cells and increase enhances the sensitivity of anticancer agents in xenograft mice model . Cepharanthine shows inhibitory effects of human liver cytochrome P450 enzymes CYP3A4, CYP2E1 and CYP2C9. Cepharanthine has antitumor, anti-inflammatory and antinociceptive effects .

HY-N0920R

Dihydrokavain (Standard) 7,8-Dihydrokawain (Standard); 7,8-Dihydrokavain (Standard); Marindinin (Standard)	Structural Classification Natural Products other families Plants Source Classification	Reference Standards COX Cytochrome P450
Dihydrokavain (Standard) (7,8-Dihydrokawain (Standard)) is the analytical standard of Dihydrokavain (HY-N0920). This product is intended for research and analytical applications. Dihydrokavain is a natural kavalactone compound. Dihydrokavain inhibits COX-1, COX-2, *CYP2C9* (IC₅₀ = 130.95 μM), CYP2C19 (IC₅₀ = 10.05 μM) and CYP3A4 (IC₅₀ = 78.59 μM). Dihydrokavain reduces TNFα secretion. Dihydrokavain shows analgesic and anxiolytic effects.

HY-N0043R

Ginsenoside Rd (Standard) Gypenoside VIII (Standard)	Panax ginseng C. A. Meyer Cardiovascular Disease Triterpenes Structural Classification Classification of Application Fields Terpenoids Plants Endogenous metabolite Disease Research Fields Araliaceae Source Classification Cancer	Reference Standards NF-κB COX Calcium Channel Cytochrome P450 Endogenous Metabolite
Ginsenoside Rd (Standard) is the analytical standard of Ginsenoside Rd. This product is intended for research and analytical applications. Ginsenoside Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC50 of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of COX-2 and iNOS mRNA. Ginsenoside Rd also inhibits Ca2+ influx. Ginsenoside Rd inhibits CYP2D6, CYP1A2, CYP3A4, and CYP2C9, with IC50s of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM, and 85.1±9.1 μM, respectively.

Cat. No.	Product Name	Chemical Structure

HY-15550S

4'-Hydroxy diclofenac-d4
4'-Hydroxy diclofenac-d₄ is the deuterium labeled 4'-Hydroxy diclofenac. 4'-Hydroxy diclofenac is an orally active metabolite of Diclofenac (HY-15036) by cytochrome P450 2C9 (CYP2C9). 4'-Hydroxy diclofenac has anti-inflammatory and analgesic properties .

HY-17356S

Fenofibrate-d6
Fenofibrate-d₆ is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-B0113S

Omeprazole-d3

1 Publications Verification

Omeprazole-d₃ (H 16868-d₃) is deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .

HY-100641S

4-Hydroxytolbutamide-d9
4-Hydroxytolbutamide-d₉ is the deuterium labeled 4-Hydroxytolbutamide. 4-Hydroxytolbutamide (Hydroxytolbutamide) is a metabolite of Tolbutamide. 4-Hydroxytolbutamide is metabolized by CYP2C8 and CYP2C9. Tolbutamide is a first generation potassium channel blocker and a sulfonylurea oral antidiabetic .

HY-B0113S3

Omeprazole-13C,d3

Omeprazole- ¹³C,d₃ is a ¹³C-labeled and deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .

HY-N1201S

Apigenin-d5
Apigenin-d5 is a deuterated labeled Apigenin . Apigenin (4',5,7-Trihydroxyflavone) is a competitive *CYP2C9* inhibitor with a K_i of 2 μM.

HY-B0258S

Gemfibrozil-d6
Gemfibrozil-d₆ is the deuterium labeled Gemfibrozil. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-13463BS

Avatrombopag-d8 hydrochloride

Avatrombopag-d₈ (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC₅₀=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

HY-15550S1

4'-Hydroxy diclofenac-13C6
4'-Hydroxy diclofenac- ¹³C₆ is the ¹³C labeled 4'-Hydroxy diclofenac . 4'-Hydroxy diclofenac is an orally active metabolite of Diclofenac (HY-15036) by cytochrome P450 2C9 (CYP2C9). 4'-Hydroxy diclofenac has anti-inflammatory and analgesic properties .

HY-N1201S1

Apigenin-13C
Apigenin- ¹³C is the ¹³C-abeled Apigenin (HY-N1201). Apigenin is a competitive CYP2C9 inhibitor with a K_i of 2 μM .

HY-N0893S

Tetrahydrocurcumin-d6
Tetrahydrocurcumin-d₆ is a deuterium labeled Tetrahydrocurcumin. Tetrahydrocurcumin is a Curcuminoid which displays inhibitory activity for CYP2C9 and CYP3A4 .

HY-B0258S1

Gemfibrozil-d6-1
Gemfibrozil-d6-1 (CI-719-d6-1) is the deuterium labeled Gemfibrozil (HY-B0258). Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively .

HY-17356S2

Fenofibrate-13C6
Fenofibrate-13C6 is a deuterated labeled Fenofibrate . Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, *CYP2C9, CYP2C8, and CYP3A4*, respectively.

HY-17356S1

Fenofibrate-d4
Fenofibrate-d₄ is the deuterium labeled Fenofibrate . Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively .

HY-100386S

Ticlopidine-d4

Ticlopidine-d₄ is the deuterium labeled Ticlopidine. Ticlopidine (PCR 5332), an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC₅₀ of 81.7 μM. Ticlopidine blocks several NTPDase isoenzymes with IC₅₀s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively . Ticlopidine is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine inhibits CYP2C9 and CYP3A4 with IC₅₀s of 26.0 and 32.3 μM, respectively .

HY-B0153AS

Ticlopidine-d4 hydrochloride

Ticlopidine-d₄ hydrochloride is the deuterium labeled Ticlopidine hydrochloride (HY-B0153A). Ticlopidine (PCR 5332) hydrochloride, an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC₅₀ of 81.7 μM. Ticlopidine hydrochloride blocks several NTPDase isoenzymes with IC₅₀s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively . Ticlopidine hydrochloride is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine hydrochloride inhibits CYP2C9 and CYP3A4 with IC₅₀s of 26.0 and 32.3 μM, respectively .

HY-W707554

Ticlopidine hydrochloride-d6

Ticlopidine hydrochloride-d₆ is the deuterium labeled Ticlopidine hydrochloride (HY-B0153A). Ticlopidine (PCR 5332) hydrochloride, an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC₅₀ of 81.7 μM. Ticlopidine hydrochloride blocks several NTPDase isoenzymes with IC₅₀s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively . Ticlopidine hydrochloride is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine hydrochloride inhibits CYP2C9 and CYP3A4 with IC₅₀s of 26.0 and 32.3 μM, respectively .

HY-76520S

Sitaxsentan-13C6

Sitaxsentan- ¹³C₆ (IPI 1040- ¹³C₆) is ¹³C labeled Sitaxsentan (HY-76520). Sitaxsentan (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC₅₀ of 1.4 nM and a K_i of 0.43 nM. Sitaxsentan exhibits an IC₅₀ for the ETB receptor of as high as 9800 nM. Sitaxsentan is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension .

HY-163816

Antiproliferative agent-53-d3

Antiproliferative agent-53-d3 (Compound C1) is an inhibitor for theta-mediated end joining (TMEJ) in HEK293 cell with an IC₅₀ of 0.14 µM. Antiproliferative agent-53-d3 is the inhibitor for CYP2C19 and CYP2C9 with IC₅₀ of 0.77 and 3.1 µM. Antiproliferative agent-53-d3 inhibits the proliferation of DNA repair-compromised cells, with IC₅₀ of 8.1 µM for BRCA2 ^-/- DLD-1. Antiproliferative agent-53-d3 exhibits good pharmacokinetic characteristics in CD-1 mice .

HY-B0113S4

Omeprazole-d3 sodium

Omeprazole-d₃ sodium is deuterated labeled Omeprazole (HY-B0113). Omeprazole sodium (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole sodium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole sodium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole sodium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole sodium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole sodium aslo has neuroprotective and antibacterial effects .

HY-B1218S

Sulfaphenazole-d4

Sulfaphenazole-d₄ is the deuterium labeled Sulfaphenazole (HY-B1218). Sulfaphenazole is a selective inhibitor of human cytochrome P450 (CYP) 2C9 enzyme. Sulfaphenazole is a cytoprotective agent against light-induced death of photoreceptors. Sulfaphenazole inhibits light-induced necrosis and mitochondrial stress-initiated apoptosis. Sulfaphenazole is an off patent sulfonamide antibiotic and demonstrates bactericidal activity through enhanced M1 macrophage activity. Sulfaphenazole can significantly reduce infarct size and restore post-ischemic coronary flow following ischemia and reperfusion .

HY-B0113S2

Omeprazole sulfone (methoxy-d3)

Omeprazole sulfone (methoxy-d₃) is the deuterium labeled Omeprazole sulfone. Omeprazole sulfone (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole sulfone competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole sulfone inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole sulfone inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole sulfone alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole sulfone aslo has neuroprotective and antibacterial effects .

HY-B0113S5

Omeprazole-d6

Omeprazole-d₆ (H 16868-d₆) is deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .

HY-B0113S1

Omeprazole-d3-1

Omeprazole-d₃-1 is the deuterium labeled Omeprazole. Omeprazole-1 (H 16868) is an orally active H ⁺,K ⁺-ATPase inhibitor and a proton pump inhibitor. Omeprazole-1 competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole-1 inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole-1 inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole-1 alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole-1 aslo has neuroprotective and antibacterial effects .

HY-166530S

Ticlopidine-d6 hydrochloride

Ticlopidine-d₆ hydrochloride is the deuterium labeled Ticlopidine hydrochloride. Ticlopidine (PCR 5332) hydrochloride, an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC₅₀ of 81.7 μM. Ticlopidine hydrochloride blocks several NTPDase isoenzymes with IC₅₀s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively . Ticlopidine hydrochloride is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine hydrochloride inhibits CYP2C9 and CYP3A4 with IC₅₀s of 26.0 and 32.3 μM, respectively .

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P82421

	*Cytochrome P450 2C9* Antibody (YA2166)** CPC9; CYP2C; CYP2C10; CYP2C9; CYPIIC9; P450 PB1; P450MP	WB, ICC/IF, FC	Human
	Cytochrome P450 2C9 Antibody (YA2166) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cytochrome P450 2C9.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-114759

MS-PPOH 1 Publications Verification		Alkynes
MS-PPOH is a potent and selective cytochrome P450 (CYP) epoxygenase inhibitor . MS-PPOH inhibits CYP2C8 and *CYP2C9* with IC₅₀s of 15 and 11 μM, respectively . MS-PPOH is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17356G

Fenofibrate	Cytochrome P450 PPAR Autophagy	Cardiovascular Disease
Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, *CYP2C9, CYP2C8, and CYP3A4*, respectively.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

2C9

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

GMP Molecules

Natural
Products